Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | IL2 | P60568 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 7/20 | 0.32 |
| ▸ | HTR2A | P28223 | 5/20 | 0.32 |
| ▸ | HTR2B | P41595 | 2/20 | 0.32 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8945540 | 0.80 | RARB (0.36) | IL2ALDH1A1HTR2CHTR2AHTR2B | |
| SCHEMBL12172444 | 0.76 | HTR2C (0.39) | TSHRGAAHPGDALDH1A1HTR2C | |
| SCHEMBL27948060 | 0.76 | ADRB2 (0.42) | TSHRGAAHPGDMAPK1HSD17B10 | |
| SCHEMBL14015538 | 0.75 | HTR2C (0.43) | TSHRGAAHPGDALDH1A1MAPK1 | |
| SCHEMBL12999938 | 0.74 | FEN1 (0.37) | TSHRGAAIL2ALDH1A1HTR2C | |
| SCHEMBL13000423 | 0.74 | DGAT1 (0.37) | TSHRGAASQORHTR2CHTR2A | |
| SCHEMBL8942338 | 0.74 | CTSL (0.35) | GAAALDH1A1HSD17B10HTR2CHTR2A | |
| SCHEMBL10302038 | 0.74 | SCD (0.33) | DGAT1 | |
| SCHEMBL12999649 | 0.73 | GAA (0.35) | TSHRGAAHPGDALDH1A1MAPK1 | |
| SCHEMBL12738858 | 0.73 | CTSS (0.35) | HPGDALDH1A1HTR2CHTR2BLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8187494-B2 | Four- or five-ring liquid crystal compound having lateral fluorine, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2012-05-29 | — | — | US | disclosed |
| US-8187494-B2 | Four- or five-ring liquid crystal compound having lateral fluorine, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2012-05-29 | — | — | US | disclosed |
| US-20100309402-A1 | FOUR- OR FIVE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100309402-A1 | FOUR- OR FIVE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | KIF23, HCN3, FZD7 | TSHR 3244/4885GAA 4800/4885IL2 2765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.